Biogen sets pricing for new MS drug

04/1/2013 | Yahoo

Biogen Idec said it would price its newly approved multiple sclerosis drug Tecfidera at $54,900 annually, lower than those of rivals including Novartis' Gilenya but higher than analysts had forecast.

View Full Article in:

Yahoo